Adjuvant breast cancer: which clinical and pathological characteristics in 2007?

被引：8

作者：

Penault-Llorca, F. ^{[1
,2
]}

Arnould, L. ^{[3
]}

机构：

[1] Ctr Jean Perrin, Serv Anatomopathol, F-63011 Clermont Ferrand, France

[2] Univ Auvergne, Fac Med & Pharm, EA 4233, F-63000 Clermont Ferrand, France

[3] Ctr Reg Lutte Canc Bourgogne, Ctr GF Leclerc, Serv Pathol, F-21000 Dijon, France

来源：

BULLETIN DU CANCER | 2010年 / 97卷 / 12期

关键词：

epidemiology; breast cancer; HER2; gene; cancer stage; SURVIVAL; HER-2; IMMUNOHISTOCHEMISTRY; AMPLIFICATION; EXPRESSION; FREQUENCY; RECEPTOR;

D O I：

10.1684/bdc.2010.1223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To refine available epidemiological data in early breast cancer, a national and retrospective study analyzed 1,934 cases listed between May and July 2007 by 88 French centers. More than one third of patients had less than 50 years old (26%) or more than 74 (15%). The anatomopathological tumors' characteristics were as following: <= 2 cm in 62% of cases, lymphatic invasion in 35% of cases, positive hormone receptors in 85% of cases, and SBR grade III in 18% of cases. The assessment of HER2 status, performed in 1,899 cases (98%), showed at least 12.1% of early stage HER2 positive tumors. HER2 overexpression was higher before 50 years old (15.9 versus 11.5% between 50 and 70 years, and 10.0% if >= 70 years old), for the largest tumors (pT2/3/4: 15.9%, < 1 cm: 11.4%, between 1 and 2 cm: 9.0%) or for a high SBR grade (III: 24.7%, II: 12.1%, I: 3.5%). This study allowed to emphasize the prevalence of HER2 overexpression in elderly patients and for small size tumors.

引用

页码：1421 / 1426

页数：6

共 27 条

[1]

Acosta G., 2001, European Journal of Cancer, V37, pS241, DOI 10.1016/S0959-8049(01)81382-4

[2]

[Anonymous], B EPIDEMIOLOGIQUE HE

[3] Mammography of ductal carcinoma in situ of the breast:: Review of 909 cases with radiographic-pathologic correlations [J].

Barreau, A ;

de Mascarel, I ;

Feuga, C ;

MacGrogan, G ;

Dilhuydy, MH ;

Picot, W ;

Dilhuydy, JM ;

de Lara, CT ;

Bussières, E ;

Schreer, I .

EUROPEAN JOURNAL OF RADIOLOGY, 2005, 54 (01) :55-61

[4]

BAUDIER F, 2007, BEH, V17, P142

[5]

CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO

[6]

2-H

[7] Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers [J].

Chia, Stephen ;

Norris, Brian ;

Speers, Caroline ;

Cheang, Maggie ;

Gilks, Blake ;

Gown, Allen M. ;

Huntsman, David ;

Olivotto, Ivo A. ;

Nielsen, Torsten O. ;

Gelmon, Karen .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5697-5704

[8] The new generation of breast cancer clinical trials: the right drug for the right target [J].

De Azambuja, Evandro ;

Cardoso, Fatima ;

Meirsman, Livia ;

Straehle, Carolyn ;

Dolci, Stella ;

Vantongelen, Kris ;

Piccart-Gebhart, Martine .

BULLETIN DU CANCER, 2008, 95 (03) :352-357

[9] Radiological features and pathological-biological correlations in 348 women with breast cancer under 35 years old [J].

Di Nubila, Brunella ;

Cassano, Enrico ;

Urban, Linei A. B. D. ;

Fedele, Palmina ;

Abbate, Francesca ;

Maisonneuve, Patrick ;

Veronesi, Paolo ;

Renne, Giuseppe ;

Bellorni, Massimo .

BREAST, 2006, 15 (06) :744-753

[10] Estimates of the cancer incidence and mortality in Europe in 2006 [J].

Ferlay, J. ;

Autier, P. ;

Boniol, M. ;

Heanue, M. ;

Colombet, M. ;

Boyle, P. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :581-592

← 1 2 3 →